[18]F-fluoroethyl-l-tyrosine positron emission tomography for radiotherapy target delineation: Results from a Radiation Oncology credentialing program
- Author(s)
- Barry, N; Koh, ES; Ebert, MA; Moore, A; Francis, RJ; Rowshanfarzad, P; Hassan, GM; Ng, SP; Back, M; Chua, B; Pinkham, MB; Pullar, A; Phillips, C; Sia, J; Gorayski, P; Le, H; Gill, S; Croker, J; Bucknell, N; Bettington, C; Syed, F; Jung, K; Chang, J; Bece, A; Clark, C; Wada, M; Cook, O; Whitehead, A; Rossi, A; Grose, A; Scott, AM;
- Journal Title
- Physics and Imaging in Radiation Oncology
- Publication Type
- Research article
- Abstract
- BACKGROUND AND PURPOSE: The [18]F-fluoroethyl-l-tyrosine (FET) PET in Glioblastoma (FIG) study is an Australian prospective, multi-centre trial evaluating FET PET for newly diagnosed glioblastoma management. The Radiation Oncology credentialing program aimed to assess the feasibility in Radiation Oncologist (RO) derivation of standard-of-care target volumes (TV(MR)) and hybrid target volumes (TV(MR+FET)) incorporating pre-defined FET PET biological tumour volumes (BTVs). MATERIALS AND METHODS: Central review and analysis of TV(MR) and TV(MR+FET) was undertaken across three benchmarking cases. BTVs were pre-defined by a sole nuclear medicine expert. Intraclass correlation coefficient (ICC) confidence intervals (CIs) evaluated volume agreement. RO contour spatial and boundary agreement were evaluated (Dice similarity coefficient [DSC], Jaccard index [JAC], overlap volume [OV], Hausdorff distance [HD] and mean absolute surface distance [MASD]). Dose plan generation (one case per site) was assessed. RESULTS: Data from 19 ROs across 10 trial sites (54 initial submissions, 8 resubmissions requested, 4 conditional passes) was assessed with an initial pass rate of 77.8 %; all resubmissions passed. TV(MR+FET) were significantly larger than TV(MR) (p < 0.001) for all cases. RO gross tumour volume (GTV) agreement was moderate-to-excellent for GTV(MR) (ICC = 0.910; 95 % CI, 0.708-0.997) and good-to-excellent for GTV(MR+FET) (ICC = 0.965; 95 % CI, 0.871-0.999). GTV(MR+FET) showed greater spatial overlap and boundary agreement compared to GTV(MR). For the clinical target volume (CTV), CTV(MR+FET) showed lower average boundary agreement versus CTV(MR) (MASD: 1.73 mm vs. 1.61 mm, p = 0.042). All sites passed the planning exercise. CONCLUSIONS: The credentialing program demonstrated feasibility in successful credentialing of 19 ROs across 10 sites, increasing national expertise in TV(MR+FET) delineation.
- Publisher
- Elsevier
- Keywords
- Clinical trials; Credentialing; Fet pet; Glioblastoma; Treatment planning
- Department(s)
- Radiation Oncology
- Publisher's Version
- https://doi.org/10.1016/j.phro.2024.100568
- Open Access at Publisher's Site
https://doi.org/10.1016/j.phro.2024.100568- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-06-27 06:18:31
Last Modified: 2024-06-27 06:47:04